Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG901 in CNGA1-Associated Retinitis Pigmentosa
NCT06291935Phase 1Recruiting
- Sponsor
- VeonGen Therapeutics
- Start
- Sep 2023
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VG901 in retinitis pigmentosa (RP), sponsored by VeonGen Therapeutics. Primary endpoint: Adverse Events and Serious Adverse Events. Started Sep 2023; status: recruiting.
02
Drugs
VG901
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT06291935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291935.